发明授权
US07994172B2 [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
失效
[1H-吡唑并[3,4-D]嘧啶-4-基] - 哌啶或哌嗪化合物，作为用于治疗免疫学，炎症和增殖性疾病的丝氨酸 - 氨氮激酶调节剂（P70s6k，Atk1和Atk2）
![[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases](/docs/US/2011-08-09/US07994172B2/abs.jpg.600x600.jpg)
- 专利标题： [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
- 专利标题（中）： [1H-吡唑并[3,4-D]嘧啶-4-基] - 哌啶或哌嗪化合物，作为用于治疗免疫学，炎症和增殖性疾病的丝氨酸 - 氨氮激酶调节剂（P70s6k，Atk1和Atk2）
-
申请号： US11722291申请日： 2005-12-27
-
公开(公告)号： US07994172B2公开(公告)日： 2011-08-09
- 发明人: Ken Rice , Erick Wang Co , Moon Hwan Kim , Lynn Canne Bannen , Joerg Bussenius , Donna Tra Le , Amy Lew Tsuhako , John Nuss , Yong Wang , Wei Xu , Rhett Ronald Klein
- 申请人： Ken Rice , Erick Wang Co , Moon Hwan Kim , Lynn Canne Bannen , Joerg Bussenius , Donna Tra Le , Amy Lew Tsuhako , John Nuss , Yong Wang , Wei Xu , Rhett Ronald Klein
- 申请人地址： US CA South San Francisco
- 专利权人： Exelixis, Inc.
- 当前专利权人： Exelixis, Inc.
- 当前专利权人地址： US CA South San Francisco
- 代理机构： McDonnell Boehnen Hulbert & Berhoff LLP
- 国际申请： PCT/US2005/046938 WO 20051227
- 国际公布： WO2006/071819 WO 20060706
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61K31/519 ; A61P35/00
![[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases](/abs-image/US/2011/08/09/US07994172B2/abs.jpg.150x150.jpg)
摘要：
The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.